BEAM: Beam Therapeutics, Inc.
About
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Current Value
$25.251 Year Return
Current Value
$25.251 Year Return
Key Details
Market Cap
$2.09B
P/E Ratio
-14.37
1Y Stock Return
-9.52%
1Y Revenue Growth
328.73%
Dividend Yield
0.00%
Price to Book
2.6
Strategies that include BEAM
Stock's related to BEAM
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRSP | 71.98% | $4.01B | -30.49% | 0.00% |
| NTLA | 67.35% | $1.44B | -50.35% | 0.00% |
| DNLI | 65.10% | $3.50B | +33.66% | 0.00% |
| RXRX | 62.89% | $1.80B | -4.13% | 0.00% |
| EDIT | 59.22% | $204.72M | -75.49% | 0.00% |
| DMRC | 55.06% | $694.39M | -2.06% | 0.00% |
| KFRC | 52.99% | $1.10B | -8.71% | 0.66% |
| CRBU | 52.96% | $180.20M | -62.45% | 0.00% |
| FATE | 52.71% | $248.29M | -11.02% | 0.00% |
| ABCL | 52.54% | $800.44M | -37.56% | 0.00% |
| PGEN | 52.51% | $228.91M | -28.00% | 0.00% |
| SOFI | 52.08% | $15.65B | +114.58% | 0.00% |
| DORM | 51.70% | $4.14B | +89.68% | 0.00% |
| ALEC | 51.69% | $377.04M | -19.46% | 0.00% |
| CWH | 51.61% | $1.36B | +5.90% | 2.22% |
| ALLO | 51.53% | $444.50M | -24.82% | 0.00% |
| BLDP | 51.45% | $398.23M | -61.89% | 0.00% |
| SCL | 51.12% | $1.69B | -6.79% | 2.01% |
| MCFT | 51.02% | $344.65M | -0.29% | 0.00% |
| TWST | 50.57% | $2.42B | +74.27% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| EDN | -0.01% | $813.00M | +161.34% | 0.00% |
| ADBE | -0.06% | $219.93B | -18.23% | 0.00% |
| FATBB | -0.06% | $81.94M | -12.91% | 11.69% |
| TGS | -0.19% | $1.97B | +116.04% | 0.00% |
| AFL | 0.37% | $61.74B | +35.69% | 1.35% |
| CMG | 0.42% | $80.02B | +33.62% | 0.00% |
| LPTH | 0.46% | $62.27M | +33.05% | 0.00% |
| KMB | -0.48% | $45.22B | +11.57% | 3.58% |
| VHC | 0.48% | $19.06M | -38.36% | 0.00% |
| CYCN | 0.54% | $4.77M | -16.19% | 0.00% |
| CEPU | 0.57% | $2.07B | +87.28% | 0.00% |
| CAH | -0.71% | $28.64B | +12.14% | 1.70% |
| GIS | -0.72% | $34.85B | -2.91% | 3.78% |
| TPST | 0.75% | $37.75M | -77.59% | 0.00% |
| WRB | 0.79% | $22.94B | +29.98% | 0.69% |
| BSX | 0.83% | $133.13B | +63.29% | 0.00% |
| MNR | 0.90% | $1.66B | -10.71% | 15.90% |
| LITB | 0.90% | $35.48M | -75.45% | 0.00% |
| EG | -0.94% | $15.92B | -8.98% | 2.02% |
| APRE | 0.96% | $16.41M | -19.47% | 0.00% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NERV | -14.21% | $14.69M | -58.00% | 0.00% |
| MCK | -13.43% | $78.15B | +35.51% | 0.42% |
| PGR | -13.16% | $149.10B | +57.29% | 0.45% |
| COR | -11.54% | $47.48B | +21.20% | 0.86% |
| CBOE | -11.42% | $21.46B | +15.84% | 1.11% |
| MNOV | -10.36% | $93.19M | +2.15% | 0.00% |
| STG | -9.62% | $35.67M | +7.92% | 0.00% |
| HUSA | -8.78% | $16.69M | -11.56% | 0.00% |
| GAN | -8.77% | $83.39M | +21.19% | 0.00% |
| ACGL | -8.41% | $36.00B | +16.84% | 0.00% |
| TCTM | -8.38% | $8.10M | -42.99% | 0.00% |
| CYD | -6.61% | $364.46M | -2.94% | 4.26% |
| BTCT | -6.43% | $42.61M | +353.33% | 0.00% |
| CHD | -6.23% | $27.18B | +19.50% | 1.03% |
| CME | -5.99% | $82.76B | +9.21% | 1.98% |
| PULM | -5.96% | $19.83M | +202.98% | 0.00% |
| AJG | -4.57% | $64.17B | +17.51% | 0.80% |
| MSDL | -4.29% | $1.83B | +0.66% | 7.26% |
| RNR | -4.04% | $13.74B | +23.09% | 0.58% |
| NHTC | -4.00% | $61.83M | +0.19% | 14.81% |
ETF's related to BEAM
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ARKG | 78.67% | $1.13B | 0.75% |
| GNOM | 76.08% | $70.59M | 0.5% |
| XBI | 71.94% | $6.58B | 0.35% |
| IWC | 67.52% | $933.99M | 0.6% |
| IWM | 66.60% | $75.73B | 0.19% |
| VTWO | 66.59% | $12.38B | 0.1% |
| IWO | 66.37% | $12.56B | 0.24% |
| PTH | 64.72% | $143.31M | 0.6% |
| ESML | 64.45% | $1.90B | 0.17% |
| NUSC | 64.35% | $1.27B | 0.31% |
| PRFZ | 64.21% | $2.65B | 0.39% |
| FYX | 64.18% | $959.00M | 0.6% |
| ISCG | 64.13% | $640.00M | 0.06% |
| IWN | 64.10% | $13.17B | 0.24% |
| ARKK | 63.80% | $6.28B | 0.75% |
| XPH | 63.53% | $157.87M | 0.35% |
| IJR | 63.34% | $90.05B | 0.06% |
| SMMD | 63.33% | $1.24B | 0.15% |
| SPSM | 63.25% | $12.72B | 0.03% |
| VIOV | 63.18% | $1.44B | 0.15% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| DBMF | 0.20% | $1.02B | 0.85% |
| SHV | 0.56% | $18.13B | 0.15% |
| JBBB | -0.70% | $1.26B | 0.49% |
| BOXX | 1.11% | $4.43B | 0.1949% |
| XBIL | -1.17% | $637.70M | 0.15% |
| GBIL | -1.22% | $5.60B | 0.12% |
| XHLF | -1.24% | $874.27M | 0.03% |
| CSHI | -1.62% | $482.85M | 0.38% |
| TBLL | 1.76% | $1.92B | 0.08% |
| HDRO | 1.85% | $164.26M | 0.3% |
| DUSB | 1.85% | $797.63M | 0.15% |
| SGOV | -2.00% | $27.53B | 0.09% |
| HIGH | -2.13% | $302.78M | 0.51% |
| KRBN | 2.18% | $242.47M | 0.85% |
| JUCY | 2.59% | $324.29M | 0.6% |
| SOYB | 3.57% | $27.32M | 0.22% |
| DBO | 4.03% | $217.57M | 0.77% |
| FBY | 4.04% | $127.69M | 0.99% |
| DBE | 4.31% | $50.13M | 0.77% |
| CCOR | 4.46% | $109.04M | 1.18% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -56.16% | $388.04M | 1.43% |
| VIXY | -30.07% | $195.31M | 0.85% |
| USDU | -20.81% | $201.97M | 0.5% |
| TAIL | -18.52% | $67.98M | 0.59% |
| UUP | -18.18% | $309.25M | 0.77% |
| CTA | -13.19% | $350.27M | 0.78% |
| EQLS | -10.95% | $76.08M | 1% |
| DBA | -10.81% | $755.88M | 0.93% |
| AGZD | -9.64% | $142.76M | 0.23% |
| KMLM | -8.94% | $353.87M | 0.9% |
| WEAT | -8.83% | $120.27M | 0.28% |
| CORN | -8.51% | $61.12M | 0.2% |
| KCCA | -7.73% | $220.51M | 0.87% |
| CLOI | -7.55% | $715.40M | 0.4% |
| TBIL | -7.41% | $4.38B | 0.15% |
| MINT | -6.04% | $11.62B | 0.35% |
| BILZ | -5.43% | $563.02M | 0.14% |
| BSCO | -4.88% | $2.35B | 0.1% |
| HIGH | -2.13% | $302.78M | 0.51% |
| SGOV | -2.00% | $27.53B | 0.09% |
News
Yahoo
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer of Beam, plans to participate in a fireside chat during the 2024 Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. GMT in London. A live webcast will be available in the investor section of the company's website at www.beamtx.com and
SeekingAlpha
Stay updated on Beam Therapeutics Inc.'s latest advancements in Sickle Cell Disease and alpha-1 antitrypsin deficiency treatments. Click for my BEAM stock update.
Yahoo
Leerink upgraded Beam Therapeutics (BEAM) to Outperform from Market Perform with a price target of $39, up from $27. The firm notes that prior to Tuesday’s BEAM-101 data in sickle-cell disease, risk of a safety signal kept Leerink on the sidelines. Following disclosure of a patient death, shares opened down over 10%, but recovered over the day, as focus shifted to BEAM-301 data in alpha-1 antitrypsin deficiency, where the firm sees a far more attractive risk/reward. Leerink takes this opportunit
Yahoo
BEAM's third-quarter 2024 earnings and revenues miss estimates. The company remains focused on pipeline development. Stock rises in pre-market.
Yahoo
Beam Therapeutics ( NASDAQ:BEAM ) Third Quarter 2024 Results Key Financial Results Revenue: US$14.3m (down 17% from 3Q...
Yahoo
Beam Therapeutics Inc (BEAM) reports encouraging clinical data for BEAM-101 in sickle cell treatment, while maintaining a strong financial position and advancing innovative gene editing programs.
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.